We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
A phase II study of the halichondrin B analog eribulin mesylate in gemcitabine refractory advanced pancreatic cancer.
- Authors
Renouf, Daniel J; Tang, Patricia A; Major, Pierre; Krzyzanowska, Monika K; Dhesy-Thind, Bindi; Goffin, John R; Hedley, David; Wang, Lisa; Doyle, L; Moore, Malcolm J
- Abstract
Eribulin mesylate is a halichondrin B analog that inhibits microtubule dynamics. Pre-clinical studies have suggested anti-tumor activity in pancreatic cancer. This phase II study of eribulin in patients with advanced pancreatic cancer previously treated with gemcitabine was conducted by the Princess Margaret Hospital Phase II consortium.
- Publication
Investigational new drugs, 2012, Vol 30, Issue 3, p1203
- ISSN
1573-0646
- Publication type
Journal Article
- DOI
10.1007/s10637-011-9673-x